567 related articles for article (PubMed ID: 28274140)
81. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
[TBL] [Abstract][Full Text] [Related]
82. Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.
Aroda VR; Frias JP; Ji L; Niemoeller E; Nguyên-Pascal ML; Denkel K; Espinasse M; Guo H; Baek S; Choi J; Lingvay I
Diabetes Obes Metab; 2023 Aug; 25(8):2084-2095. PubMed ID: 37013892
[TBL] [Abstract][Full Text] [Related]
83. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
Mari A; Del Prato S; Ludvik B; Milicevic Z; de la Peña A; Shurzinske L; Karanikas CA; Pechtner V
Diabetes Obes Metab; 2016 Aug; 18(8):834-9. PubMed ID: 27059816
[TBL] [Abstract][Full Text] [Related]
84. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC; Lopez-Jaramillo P; Lanas F; Munoz EGC; Pirags V; Pogosova N; Basile J; Sheu WHH; Temelkova-Kurktschiev T; Raubenheimer PJ; Keltai M; Hall S; Pais P; Colhoun HM; Riddle MC; Gerstein HC
Cardiovasc Diabetol; 2020 Nov; 19(1):199. PubMed ID: 33239067
[TBL] [Abstract][Full Text] [Related]
85. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.
Morieri ML; Rigato M; Frison V; Simioni N; D'Ambrosio M; Tadiotto F; Paccagnella A; Lapolla A; Avogaro A; Fadini GP
Metabolism; 2020 May; 106():154190. PubMed ID: 32109448
[TBL] [Abstract][Full Text] [Related]
86. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
Tanaka K; Okada Y; Tokutsu A; Tanaka Y
Sci Rep; 2022 Jan; 12(1):154. PubMed ID: 34997102
[TBL] [Abstract][Full Text] [Related]
87. ACP Journal Club: in metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels.
Morey-Vargas OL; Shah P
Ann Intern Med; 2014 Nov; 161(10):JC9. PubMed ID: 25402542
[No Abstract] [Full Text] [Related]
88. [Dulaglutide and liraglutide compared].
Bruhn C
Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
[No Abstract] [Full Text] [Related]
89. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC
Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224
[TBL] [Abstract][Full Text] [Related]
90. Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).
Yu M; Brunt KV; Milicevic Z; Varnado O; Boye KS
Clin Ther; 2017 Nov; 39(11):2284-2295. PubMed ID: 29110972
[TBL] [Abstract][Full Text] [Related]
91. A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide.
An IB; Byun MS; Yang SI; Choi Y; Woo JW; Jang HC; Sung YC
Diabetes Obes Metab; 2020 Aug; 22(8):1455-1468. PubMed ID: 32314505
[TBL] [Abstract][Full Text] [Related]
92. Improved Clinical Outcomes with Dulaglutide as Add-on Medication to Oral Antidiabetic Drugs with or Without Insulin in Overweight Indian Patients with Type 2 Diabetes Mellitus: Retrospective Study in a Real-World Setting.
Ghosh A; Nair R
Curr Diabetes Rev; 2020; 16(5):490-496. PubMed ID: 31686642
[TBL] [Abstract][Full Text] [Related]
93. The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus.
Wang J; Li HQ; Xu XH; Kong XC; Sun R; Jing T; Ye L; Su XF; Ma JH
Biomed Res Int; 2019; 2019():2682657. PubMed ID: 31950036
[No Abstract] [Full Text] [Related]
94. A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.
Emoto M; Terauchi Y; Ozeki A; Oura T; Takeuchi M; Imaoka T
Endocr J; 2015; 62(12):1101-14. PubMed ID: 26477324
[TBL] [Abstract][Full Text] [Related]
95. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.
Jimenez-Solem E; Rasmussen MH; Christensen M; Knop FK
Curr Opin Mol Ther; 2010 Dec; 12(6):790-7. PubMed ID: 21154170
[TBL] [Abstract][Full Text] [Related]
96. Dulaglutide for the treatment of type 2 diabetes.
Amblee A
Drugs Today (Barc); 2014 Apr; 50(4):277-89. PubMed ID: 24918645
[TBL] [Abstract][Full Text] [Related]
97. [Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)].
Tamaki C; Takeuchi M; Iwamoto N; Glaesner W
Nihon Yakurigaku Zasshi; 2015 Oct; 146(4):215-24. PubMed ID: 26656966
[No Abstract] [Full Text] [Related]
98. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.
Mody R; Grabner M; Yu M; Turner R; Kwan AYM; York W; Fernández Landó L
Curr Med Res Opin; 2018 Jun; 34(6):995-1003. PubMed ID: 29271258
[TBL] [Abstract][Full Text] [Related]
99. Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.
Romera I; Conget I; Vazquez LA; Gentilella R; Lebrec J; Jódar E; Reviriego J
J Diabetes Complications; 2020 Jul; 34(7):107575. PubMed ID: 32220551
[TBL] [Abstract][Full Text] [Related]
100. Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis.
Xu J; Yao D; Xia J
J Clin Pharm Ther; 2021 Oct; 46(5):1245-1253. PubMed ID: 33675117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
